Abiomed, Inc. preliminary revenue results for the third quarter of fiscal year 2017. For the quarter, the company reported revenue of approximately $114.7 million, an increase of 34% compared to revenue of $85.8 million for the same period of fiscal 2016.

The company is maintaining its fiscal year 2017 revenue guidance of $435 million to $445 million, an increase in revenue of 32% to 35% from the prior year. The company is also maintaining its fiscal year guidance for GAAP operating margin to be in the range of 18% to 20%. For third quarter of fiscal 2017, the US patient usage grew 32% in comparison with same period of fiscal 2016.